The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Oral anti-diabetic agents have been associated with adverse cardiovascular events in type 2 diabetes (DM2). We investigated the risk of coronary artery disease (CAD), congestive heart failure (CHF), and mortality using multivariable Cox models in a retrospective cohort of 20,450 DM2 patients from our electronic health record (EHR). We observed no differences in CAD risk among the agents. Metformin was associated with a reduced risk of CHF (HR 0.76, 95% CI 0.64-0.91) and mortality (HR 0.54, 95% CI 0.46-0.64) when compared to sulfonylurea. Pioglitazone was also associated with a lower risk of mortality when compared to sulfonylurea (HR 0.59, 95% CI 0.43-0.81). No other significant differences were found between the oral agents. In conclusions, our results did not identify an increased CAD risk with rosiglitazone in clinical practice. However, the results do reinforce a possible increased risk of adverse events in DM2 patients prescribed sulfonylureas.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, in the UKPDS, NAVIGATOR (Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research), and ADOPT trials, there were no increased HF signals.127,[562][563][564]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [562]
Citations
Cites
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
(1970) · PubMed · Cited by 976
Nissen, S. E., Nicholls, S. J., Wolski, K., Nesto, R., Kupfer, S., Perez, A., Jure, H., De Larochellière, R., Staniloae, C. S., Mavromatis, K., et al. (2008) · JAMA · doi:10.1001/jama.299.13.1561 · Cited by 850
Cited by
Items 101–126 of 126
Berberoğlu, Z., Yazıcı, A. C., Bayraktar, N., & Demirağ, N. G. (2011) · Acta Diabetologica · doi:10.1007/s00592-011-0352-3 · Cited by 4
Heart failure in diabetes: effects of anti-hyperglycemic drug therapy
Galstyan, G. R., & Gilyarov, M. Y. (2016) · Diabetes Mellitus · doi:10.14341/dm2003451-57 · Cited by 4
Vildagliptin for the treatment of diabetes
Samraj, G. P. N. (2011) · Therapy · doi:10.2217/thy.11.75 · Cited by 4
Metformin: od mehanizmov delovanja do napredne klinične uporabe
Janić, M., Volčanšek, Š., Lunder, M., & Janež, A. (2017) · Slovenian Medical Journal · doi:10.6016/zdravvestn.1503 · Cited by 4
The treatment of type 2 diabetes in heart failure
Llano, A., & McKay, G. (2018) · Practical Diabetes · doi:10.1002/pdi.2178 · Cited by 3
Ruzafa, J. C., Ulrichsen, S. P., Bennett, D., & Ehrenstein, V. (2019) · Drugs - Real World Outcomes · doi:10.1007/s40801-019-0160-6 · Cited by 3
Which drug is best for a patient with type 2 diabetes and heart failure?
Clawson, R., Weidman-Evans, E., & Fort, A. (2021) · JAAPA · doi:10.1097/01.jaa.0000743004.83284.cc · Cited by 3
Vércukorcsökkentő gyógyszerek biztonságossága szívelégtelenségben
Frigy, A., Germán-Salló, M., Máthé, L., & Szabó, M. (2017) · Orvosi Hetilap · doi:10.1556/650.2017.30652 · Cited by 3
Insulin, other hypoglycemic drugs, and glucagon
Page, R. C. (2010) · Side effects of drugs annual · doi:10.1016/s0378-6080(10)32042-3 · Cited by 2
Diabetes and cardiovascular disease
Guamán, C., Acosta, W. S., Alvarez, C., & Hasbum, B. (2023) · Cardiac and Cardiovascular Research · doi:10.54517/ccr.v4i2.1918 · Cited by 2
Davidson, M. (2018) · uO Research (University of Ottawa) · doi:10.20381/ruor-22317 · Cited by 2
Prevention of type 2 diabetes in patients with chronic heart failure
Павликова, Е. П., Sorokina, A. G., & Potapenko, A. V. (2020) · Clinical pharmacology and therapy · doi:10.32756/0869-5490-2020-1-67-74 · Cited by 1
Kim, S. S., & Kim, I. J. (2021) · Stroke revisited · doi:10.1007/978-981-16-5123-6_9 · Cited by 1
(2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53717-1.01536-5 · Cited by 1
Role of ACE Inhibitors and Angiotensin Receptor Blockers in Peripheral Artery Disease
Nandave, M. (2024) · Springer eBooks · doi:10.1007/978-981-97-7380-0_8 · Cited by 1
Editorial commentary: Anti-glycemic drugs and heart failure—A new era
FITCHETT, D. H. (2016) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2016.08.005 · Cited by 1
Faillie, J. (2014) · Thèses en ligne de l'Université Toulouse III (Université Toulouse III)
Bell, D. S. H. (2009) · Acta Diabetologica · doi:10.1007/s00592-009-0106-7
Abdelmoneim, A. (2015) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r30c4sw67
Current literature in diabetes
(2009) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1046
Luca, M. D., Bosso, G., Valvano, A., Guardasole, V., Botta, A., Carbone, V., Carella, G., Buono, A. D., Giovanni, G. D., Fimiani, B., et al. (2020) · Research Square · doi:10.21203/rs.3.rs-27651/v1
Thakkar, H. V., & Negishi, K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-64067-1.00028-0
Айтбаев, К. А., Murkamilov, I. T., Fomin, V. V., Абдилалимовна, М. Ж., Kudaibergenova, I., & Yusupov, F. A. (2023) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2023-3457
Pan, Y., Davis, P. B., Kaebler, D. C., Blankfield, R. P., & Xu, R. (2022) · Figshare · doi:10.6084/m9.figshare.20786767
Marx-Schütt, K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00016-1
Diretriz Brasileira de Insuficiência Cardíaca – 2026
Simões, M. V., Moura, L. Z., Martins, S. M., Mourilhe‐Rocha, R., Danzmann, L. C., Neto, J. A. D. F., Marcondes‐Braga, F. G., de Oliveira, M. T., de Albuquerque, D. C., Freitas, A. F., et al. (2026) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20260830 · Cited by 1
Metadata
- Authors
- Pantalone, K. M., Kattan, M. W., Yu, C., Wells, B. J., Arrigain, S., Jain, A., Atreja, A., & Zimmerman, R. S.
- Affiliations
- Cleveland Clinic (US)
- Corresponding author
- Pantalone, Kevin M.
- ORCID
- Venue
- Acta Diabetologica
- Published
- 2009-02-05
- Volume
- 46
- Issue
- 2
- Pages
- 145-154
- ISSN
- 0940-5429 (ISSN-L)
- 1432-5233
- OpenAlex
- W2020353068
- Cited by
- 123
- References
- 25
- Citations by year
- 2026: 2 · 2024: 2 · 2023: 2 · 2022: 4 · 2021: 8 · 2020: 11 · 2019: 11 · 2018: 9 · 2017: 12 · 2016: 10 · 2015: 10 · 2014: 3 · 2013: 5 · 2012: 8
- FWCI
- 7.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Acta Diabetologica (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- type 2 diabetes, rosiglitazone, pioglitazone, metformin, sulfonylureas, coronary artery disease, congestive heart failure, all-cause mortality, cardiovascular adverse events, oral antidiabetic drugs, drug safety
- MeSH terms
- Rosiglitazone, Angiotensin-Converting Enzyme Inhibitors, Coronary Artery Bypass, Coronary Disease, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Female, Heart Failure, Humans, Hypoglycemic Agents, Male, Metformin, Retrospective Studies, Risk Factors, Smoking, Sulfonylurea Compounds, Multivariate Analysis, Proportional Hazards Models, Survival Analysis, Survivors, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.